Latest Breaking News On - Advanced cancers treated - Page 1 : comparemela.com

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into responders Objective response was observed in 60% of anti-PD-1 naïve patients and 50% of prior non-responders Data suggest abscopal effect in some patients (i.e., reduction in non-injected non-irradiated lesions) To date, the overall adverse event profile for the 16 injected patients has not differed from what is expected with radiotherapy or anti-PD-1 agents (head and neck cancer and non-small cell lung cancer primary tumors)

New yorkUnited statesFrance generalUnited kingdomBrandon owensKate mcneilColette shenPorter novelliTanguy seiwertPierre louis germainExchange commission onUniversity of texas md anderson cancer centerFrench financial markets authority autoritDrug administrationNanobiotix communicationsGiven the company